110 related articles for article (PubMed ID: 28528082)
1. Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.
Zhuang L; Tice CM; Xu Z; Zhao W; Cacatian S; Ye YJ; Singh SB; Lindblom P; McKeever BM; Krosky PM; Zhao Y; Lala D; Kruk BA; Meng S; Howard L; Johnson JA; Bukhtiyarov Y; Panemangalore R; Guo J; Guo R; Himmelsbach F; Hamilton B; Schuler-Metz A; Schauerte H; Gregg R; McGeehan GM; Leftheris K; Claremon DA
Bioorg Med Chem; 2017 Jul; 25(14):3649-3657. PubMed ID: 28528082
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.
Hamilton BS; Himmelsbach F; Nar H; Schuler-Metz A; Krosky P; Guo J; Guo R; Meng S; Zhao Y; Lala DS; Zhuang L; Claremon DA; McGeehan GM
Eur J Pharmacol; 2015 Jan; 746():50-5. PubMed ID: 25445047
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1.
Xu Z; Tice CM; Zhao W; Cacatian S; Ye YJ; Singh SB; Lindblom P; McKeever BM; Krosky PM; Kruk BA; Berbaum J; Harrison RK; Johnson JA; Bukhtiyarov Y; Panemangalore R; Scott BB; Zhao Y; Bruno JG; Togias J; Guo J; Guo R; Carroll PJ; McGeehan GM; Zhuang L; He W; Claremon DA
J Med Chem; 2011 Sep; 54(17):6050-62. PubMed ID: 21786805
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model.
Julian LD; Wang Z; Bostick T; Caille S; Choi R; DeGraffenreid M; Di Y; He X; Hungate RW; Jaen JC; Liu J; Monshouwer M; McMinn D; Rew Y; Sudom A; Sun D; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
J Med Chem; 2008 Jul; 51(13):3953-60. PubMed ID: 18553955
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.
Ye XY; Chen SY; Wu S; Yoon DS; Wang H; Hong Z; O'Connor SP; Li J; Li JJ; Kennedy LJ; Walker SJ; Nayeem A; Sheriff S; Camac DM; Ramamurthy V; Morin PE; Zebo R; Taylor JR; Morgan NN; Ponticiello RP; Harrity T; Apedo A; Golla R; Seethala R; Wang M; Harper TW; Sleczka BG; He B; Kirby M; Leahy DK; Li J; Hanson RL; Guo Z; Li YX; DiMarco JD; Scaringe R; Maxwell B; Moulin F; Barrish JC; Gordon DA; Robl JA
J Med Chem; 2017 Jun; 60(12):4932-4948. PubMed ID: 28537398
[TBL] [Abstract][Full Text] [Related]
7. Influence of sub-chronic selective 11β-hydroxysteroid dehydrogenase 1 inhibition on the hypothalamic-pituitary-adrenal axis in female cynomolgus monkeys.
Hamilton BS; Schoelch C; Schuler-Metz A; Krosky P; Lala DS; Claremon DA; McGeehan GM
Eur J Pharmacol; 2016 Oct; 789():68-74. PubMed ID: 27393460
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol inhibits 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose microsomes.
Tagawa N; Kubota S; Kato I; Kobayashi Y
J Endocrinol; 2013 Sep; 218(3):311-20. PubMed ID: 23814014
[TBL] [Abstract][Full Text] [Related]
9. 3-Amino-N-adamantyl-3-methylbutanamide derivatives as 11β-hydroxysteroid dehydrogenase 1 inhibitor.
Lee Y; Shin YJ; Ahn SK
Bioorg Med Chem Lett; 2014 Mar; 24(5):1421-5. PubMed ID: 24507919
[TBL] [Abstract][Full Text] [Related]
10. Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Su X; Pradaux-Caggiano F; Thomas MP; Szeto MW; Halem HA; Culler MD; Vicker N; Potter BV
ChemMedChem; 2010 Jul; 5(7):1026-44. PubMed ID: 20486152
[TBL] [Abstract][Full Text] [Related]
11. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
[TBL] [Abstract][Full Text] [Related]
12. Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the treatment of metabolic disorders.
Yoon DS; Wu SC; Seethala R; Golla R; Nayeem A; Everlof JG; Gordon DA; Hamann LG; Robl JA
Bioorg Med Chem Lett; 2014 Nov; 24(21):5045-9. PubMed ID: 25266782
[TBL] [Abstract][Full Text] [Related]
13. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
Roche D; Carniato D; Leriche C; Lepifre F; Christmann-Franck S; Graedler U; Charon C; Bozec S; Doare L; Schmidlin F; Lecomte M; Valeur E
Bioorg Med Chem Lett; 2009 May; 19(10):2674-8. PubMed ID: 19395260
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of picolinamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Ryu JH; Kim S; Han HY; Son HJ; Lee HJ; Shin YA; Kim JS; Park HG
Bioorg Med Chem Lett; 2015 Feb; 25(3):695-700. PubMed ID: 25529735
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 11β-hydroxysteroid dehydrogenase type 1 inhibitor.
Hong SP; Nam KY; Shin YJ; Kim KW; Ahn SK
Bioorg Med Chem Lett; 2015 Sep; 25(17):3501-6. PubMed ID: 26187704
[TBL] [Abstract][Full Text] [Related]
16. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
[TBL] [Abstract][Full Text] [Related]
17. 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Development by Lentiviral Screening Based on Computational Modeling.
Liu H; Li L; Zhang C; Li H; Liu J; Tang C; Zhang Y; Wu D; Chu Y; Wu Y; Yuan X
Pharmacology; 2018; 102(3-4):169-179. PubMed ID: 30099452
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of (R)-1-arylsulfonylpiperidine-2-carboxamides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
Xia G; Liu L; Liu H; Yu J; Xu Z; Chen Q; Ma C; Li P; Xiong B; Liu X; Shen J
ChemMedChem; 2013 Apr; 8(4):577-81. PubMed ID: 23471829
[TBL] [Abstract][Full Text] [Related]
19. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.
Hale C; Véniant M; Wang Z; Chen M; McCormick J; Cupples R; Hickman D; Min X; Sudom A; Xu H; Matsumoto G; Fotsch C; St Jean DJ; Wang M
Chem Biol Drug Des; 2008 Jan; 71(1):36-44. PubMed ID: 18069989
[TBL] [Abstract][Full Text] [Related]
20. Continuous inhibition of 11β-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice.
Morentin Gutierrez P; Gyte A; deSchoolmeester J; Ceuppens P; Swales J; Stacey C; Eriksson JW; Sjöstrand M; Nilsson C; Leighton B
Br J Pharmacol; 2015 Oct; 172(20):4806-16. PubMed ID: 26218540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
